We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




MCED Could Be Valuable Supplement to Traditional Cancer Screening Approaches

By LabMedica International staff writers
Posted on 10 Jul 2025

Current cancer screening methods are limited in scope, primarily focusing on a few high-incidence cancer types, such as those detected by mammography, colonoscopy, and low-dose computed tomography (LDCT). More...

These traditional methods often have high false-positive rates and require invasive procedures, leading to poor patient adherence and limited overall effectiveness. Additionally, detecting cancer early—when it is most treatable—remains a challenge. Liquid biopsy-based multi-cancer early detection (MCED) has been identified as a potential breakthrough, offering a non-invasive, multi-cancer diagnostic approach. By analyzing biological markers such as cfDNA, cfRNA, and proteins from blood or body fluids, MCED can detect multiple cancers simultaneously and potentially localize the tissue of origin, offering a promising solution for earlier and more effective cancer detection.

Researchers from the Chinese Academy of Medical Sciences (CACMS, Beijing, China) and collaborators have explored the road for liquid biopsy-based MCED from evidence to implementation in a paper published in Science Bulletin. The technology utilizes liquid biopsy to analyze biomarkers in blood or other body fluids, leveraging AI algorithms to enhance detection accuracy. This approach offers broad population and cancer-type coverage, minimal invasiveness, and high patient compliance. The MCED method works by analyzing cfDNA, cfRNA, and proteins to detect cancer markers, expanding screening to a wider range of cancers. While MCED holds potential, further validation through clinical trials and real-world evidence is needed to establish its clinical efficacy. The MCED method has been evaluated through various clinical trials, and results show significant promise.

The findings indicate that MCED technology offers improved sensitivity and specificity over existing screening techniques, enabling the detection of cancers earlier and with greater accuracy. The technology could also potentially reduce late-stage cancer incidence, leading to better outcomes and lower healthcare costs. However, challenges remain, such as balancing surrogate endpoints with actual public health benefits, improving early detection for cancers with low cfDNA shedding, and minimizing false positives and mislocalization errors. Researchers are working to refine the technology, focusing on clinical validation, cost control, and enhancing evidence generation to support MCED’s future implementation as a complementary tool to existing cancer screening approaches.


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Biochemical Analyzer
iBC 900
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.